InnoBation Bio Advances Multi-Modality Immuno-Oncology Portfolio
Content
Press Release
InnoBation Bio Advances Multi-Modality Immuno-Oncology Portfolio
Wilmington, DE / Seoul, Korea — February 1, 2026
InnoBation Bio / Liminatus Pharma today announced continued progress across its immuno-oncology pipeline, including next-generation CD47 blockade (IBA101) and multi-specific CAR-T platforms for solid and hematologic cancers.
- Anti-CD47 blockade (IBA101) — Solid cancers
- CD19×CD22 bivalent CAR-T — Hematologic cancer
- MSLN×CD276 bicistronic CAR-T — Solid cancer
- CD19×CD22×CS1 trivalent CAR-T — Hematologic cancer
This sample post was authored via the HTML tab to verify detail-page rendering and attachments.
Media contact (sample): info@liminatuspharma.com